{
    "body": "What is the relationship between TailorX and Oncotype?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18922117", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23411384", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20665886", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25240289", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23643806"
    ], 
    "ideal_answer": [
        "The TAILORx trial uses the Oncotype DX recurrence score to assign estrogen receptor-positive (ER+), node-negative patients to chemotherapy plus hormonal therapy versus hormonal therapy alone."
    ], 
    "type": "summary", 
    "id": "56ccae765795f9a73e000035", 
    "snippets": [
        {
            "offsetInBeginSection": 302, 
            "offsetInEndSection": 494, 
            "text": "The TAILORx trial uses the Oncotype DX recurrence score to assign estrogen receptor-positive (ER+), node-negative patients to chemotherapy plus hormonal therapy versus hormonal therapy alone. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23411384", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 274, 
            "offsetInEndSection": 551, 
            "text": "A cohort study was undertaken, including consecutive patients with early node-negative, ER-positive breast cancer diagnosed between 2006 and May 2013, including a period of prospective clinical trial (Trial Assigning Individualised Options for Treatment (TAILORx)) recruitment.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25240289", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 552, 
            "offsetInEndSection": 701, 
            "text": "Data were collected regarding patient demographics, tumour clinico-pathological features, Oncotype DX use and recurrence score and chemotherapy use. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25240289", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1029, 
            "offsetInEndSection": 1167, 
            "text": "Oncotype DX testing began on a trial basis in 2007 and until October 2011, only patients enrolled on TAILORx availed of genomic profiling.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25240289", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 885, 
            "offsetInEndSection": 1028, 
            "text": "479 consecutive patients were included in the study, of whom 241 (50%) underwent Oncotype DX testing, 97 as part of the TAILORx clinical trial.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25240289", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 928, 
            "offsetInEndSection": 1429, 
            "text": "To evaluate the ability to guide treatment decisions in the group with a mid-range recurrence score, the North American Cooperative Groups developed the Trial Assessing IndiviuaLized Options for Treatment for breast cancer, a randomized trial of chemotherapy followed by hormonal therapy versus hormonal therapy alone on invasive disease-free survival-ductal carcinoma in situ (IDFS-DCIS) survival in women with node-negative, estrogen-receptor-positive breast cancer with a recurrence score of 11-25.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18922117", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 191, 
            "offsetInEndSection": 546, 
            "text": "One of these tests, Oncotype DXtrade mark, is a diagnostic test comprised of a 21-gene assay applied to paraffin-embedded breast cancer tissue, which allows physicians to predict subgroups of hormone-receptor-positive, node-negative patients who may benefit from hormonal therapy alone or require adjuvant chemotherapy to attain the best survival outcome.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18922117", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 317, 
            "offsetInEndSection": 600, 
            "text": "We tested if Oncotype DX and TAILORx risk categories could be predicted by standard pathological features and protein markers corresponding to 10 genes in the assay (ER, PR, Ki67, HER2, BCL2, CD68, Aurora A kinase, survivin, cyclin B1 and BAG1) on 52 patients who enrolled on TAILORx", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23643806", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 302, 
            "offsetInEndSection": 492, 
            "text": "The TAILORx trial uses the Oncotype DX recurrence score to assign estrogen receptor-positive (ER+), node-negative patients to chemotherapy plus hormonal therapy versus hormonal therapy alone", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23411384", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 163, 
            "text": "Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23643806", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 139, 
            "offsetInEndSection": 602, 
            "text": "Each patient is stratified into a risk category based on a recurrence score (RS) and the TAILORx trial is determining the benefit of chemotherapy for patients with mid-range RSs. We tested if Oncotype DX and TAILORx risk categories could be predicted by standard pathological features and protein markers corresponding to 10 genes in the assay (ER, PR, Ki67, HER2, BCL2, CD68, Aurora A kinase, survivin, cyclin B1 and BAG1) on 52 patients who enrolled on TAILORx.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23643806", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 853, 
            "offsetInEndSection": 1136, 
            "text": "479 consecutive patients were included in the study, of whom 241 (50%) underwent Oncotype DX testing, 97 as part of the TAILORx clinical trial. Oncotype DX testing began on a trial basis in 2007 and until October 2011, only patients enrolled on TAILORx availed of genomic profiling.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25240289", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 303, 
            "offsetInEndSection": 402, 
            "text": "The TAILORx trial uses the Oncotype DX recurrence score to assign estrogen receptor-positive (ER+),", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23411384", 
            "endSection": "abstract"
        }
    ]
}